evaluated clinical remission in a subset of patients with severe asthma treated with benralizumab (interleukin-5 [IL-5] receptor α-directed monoclonal antibody) using data from three pivotal Phase III clinical trials (6). The gene discussed is IL5; the disease is asthma.